Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Region

NEW YORK--(BUSINESS WIRE)--Jun 1, 2024--

Related Keywords

United States ,South Korea ,Japan ,Canada ,American ,America ,Korea ,Canadian ,Roger Dansey ,Catholic University Of Korea ,American Society Of Clinical Oncology ,National Library Of Medicine ,Linkedin ,Youtube ,Exchange Commission ,College Of Medicine ,Leukemia Lymphoma Society ,Pfizer Inc ,Pfizer ,Clinical Oncology ,Annual Meeting ,Jeunga Kim ,Catholic University ,Chief Development Officer ,North America ,Diffuse Largeb Cell Lymphoma ,Prescribing Information ,Pfizer Oncology ,Breakthroughs That Change Patient Lives ,Annual Report ,Looking Information ,Factors That May Affect Future ,Diffuse Largeb Cell ,Updated April ,Media Contact ,Business Wire ,